{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T06:01:51Z","timestamp":1791352911884,"version":"4.3.1"},"reference-count":76,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2011,6,16]],"date-time":"2011-06-16T00:00:00Z","timestamp":1308182400000},"content-version":"vor","delay-in-days":15,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Neurology"],"published-print":{"date-parts":[[2011,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Existing and emerging strategies for managing L\u2010dopa\u2013induced dyskinesias (LIDs) in patients with Parkinson disease have involved either delaying the introduction of L\u2010dopa therapy, treatment with an antidyskinetic agent, using a therapy or delivery system that can provide continuous dopaminergic stimulation, or using novel agents that target receptors implicated in the mechanisms underlying LIDs. Treatment with dopamine agonists such as pramipexole or ropinirole allows levodopa to be delayed, but once levodopa is added to the drug regimen the usual course of onset of dyskinesias is observed. Amantadine, an N\u2010methyl\u2010<jats:sc>D<\/jats:sc>\u2010aspartate antagonist, is so far the only approved compound with evidence of providing a sustained antidyskinetic benefit in the absence of unacceptable side effects. These findings support the hypothesis of glutamate overactivity in the development of dyskinesias. More continuous delivery of dopaminergic medication, such as through intraintestinal or subcutaneous routes, is promising but invasive and associated with injection site reactions. As a result of molecular research and elucidation of the role of a variety of neurotransmitters in the mechanism of LIDs, new compounds have been identified, including those that modulate the direct and indirect striatal output pathways; some of these new agents are in the early stages of development or undergoing proof\u2010of\u2010concept evaluation as antidyskinetic agents. Ann Neurol 2011;69:919\u2013927<\/jats:p>","DOI":"10.1002\/ana.22423","type":"journal-article","created":{"date-parts":[[2011,3,16]],"date-time":"2011-03-16T17:29:57Z","timestamp":1300296597000},"page":"919-927","source":"Crossref","is-referenced-by-count":71,"title":["Therapies for dopaminergic\u2010induced dyskinesias in parkinson disease"],"prefix":"10.1002","volume":"69","author":[{"given":"Mildred D.","family":"Gottwald","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Aminoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,6,16]]},"reference":[{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000215250.82576.87"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1090"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196902132800701"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d90050"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20458"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.12.1756"},{"key":"e_1_2_9_8_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.2_Part_1.202"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2004.10.002"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23068"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrn2471"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22019"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1353-8020(08)70014-2"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2008.09.013"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/ncpneuro0222"},{"key":"e_1_2_9_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.62.6.905"},{"key":"e_1_2_9_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2007.06.002"},{"key":"e_1_2_9_18_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.22-12-05042.2002"},{"key":"e_1_2_9_19_2","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.5326-05.2006"},{"key":"e_1_2_9_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/nn1040"},{"key":"e_1_2_9_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23072"},{"key":"e_1_2_9_22_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200001000-00007"},{"key":"e_1_2_9_23_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.15.1931"},{"key":"e_1_2_9_24_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.61.7.1044"},{"key":"e_1_2_9_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2009.32"},{"key":"e_1_2_9_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21292"},{"key":"e_1_2_9_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422004"},{"key":"e_1_2_9_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20988"},{"key":"e_1_2_9_29_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21743"},{"key":"e_1_2_9_30_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22890"},{"key":"e_1_2_9_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22060"},{"key":"e_1_2_9_32_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22079"},{"key":"e_1_2_9_33_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.5.1323"},{"key":"e_1_2_9_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/1531-8257(200009)15:5<873::AID-MDS1017>3.0.CO;2-I"},{"key":"e_1_2_9_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200003000-00004"},{"key":"e_1_2_9_36_2","first-page":"CD003467","article-title":"Amantadine for dyskinesia in Parkinson's disease","volume":"2","author":"Crosby NJ","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_9_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.23034"},{"issue":"1","key":"e_1_2_9_38_2","first-page":"S263","article-title":"Effects of NMDA receptor antagonist on levodopa induced dyskinesias: meta analysis of controlled clinical trials","volume":"24","author":"Elahi B","year":"2009","journal-title":"Mov Disord"},{"key":"e_1_2_9_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mp.4001556"},{"key":"e_1_2_9_40_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000110317.52453.6C"},{"key":"e_1_2_9_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10589"},{"key":"e_1_2_9_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awf214"},{"key":"e_1_2_9_43_2","volume-title":"Apokyn (apomorphine) prescribing information","year":"2006"},{"key":"e_1_2_9_44_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.64.5.573"},{"key":"e_1_2_9_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.1276"},{"key":"e_1_2_9_46_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10281"},{"key":"e_1_2_9_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s100720170062"},{"key":"e_1_2_9_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)91193-2"},{"key":"e_1_2_9_49_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20276"},{"key":"e_1_2_9_50_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22063"},{"key":"e_1_2_9_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1353-8020(09)70844-2"},{"key":"e_1_2_9_52_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.9.1698"},{"key":"e_1_2_9_53_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0404.2001.00153.x"},{"key":"e_1_2_9_54_2","doi-asserted-by":"publisher","DOI":"10.1097\/wnf.0b013e31814b113e"},{"key":"e_1_2_9_55_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22450"},{"key":"e_1_2_9_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21475"},{"key":"e_1_2_9_57_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000134672.44217.F7"},{"key":"e_1_2_9_58_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-200311000-00008"},{"key":"e_1_2_9_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70012-6"},{"key":"e_1_2_9_60_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0166-2236(96)10073-4"},{"key":"e_1_2_9_61_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0308208101"},{"key":"e_1_2_9_62_2","doi-asserted-by":"publisher","DOI":"10.1159\/000216839"},{"key":"e_1_2_9_63_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.22948"},{"key":"e_1_2_9_64_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10464"},{"issue":"1","key":"e_1_2_9_65_2","first-page":"S435","article-title":"Validating rating performance of a new rating scale for levodopa\u2010induced dyskinesia (LIDS)","volume":"24","author":"LeWitt PA","year":"2009","journal-title":"Mov Disord"},{"key":"e_1_2_9_66_2","unstructured":"Santhera Pharmaceuticals.Press release: FJORD phase 2B study demonstrates efficacy of JP\u20101730\/fipamezole for the treatment of dyskinesia in Parkinson's disease. June 30 2009."},{"key":"e_1_2_9_67_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.64.7.990"},{"key":"e_1_2_9_68_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20029"},{"key":"e_1_2_9_69_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21900"},{"key":"e_1_2_9_70_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2009.05.003"},{"key":"e_1_2_9_71_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.WNF.0000220814.48360.F4"},{"key":"e_1_2_9_72_2","doi-asserted-by":"publisher","DOI":"10.1097\/wnf.0b013e318033a6c7"},{"key":"e_1_2_9_73_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20563"},{"issue":"2","key":"e_1_2_9_74_2","first-page":"S302","article-title":"Safinamide as add\u2010on to levodopa improves motor function without worsening dyskinesia in patients with mid\u2010late Parkinson's disease","volume":"25","author":"Meshram CM","year":"2010","journal-title":"Mov Disord"},{"key":"e_1_2_9_75_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.2005.069849"},{"key":"e_1_2_9_76_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2006.03.033"},{"key":"e_1_2_9_77_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000256036.20927.a5"}],"container-title":["Annals of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fana.22423","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ana.22423","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T06:42:19Z","timestamp":1697438539000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ana.22423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":76,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["10.1002\/ana.22423"],"URL":"https:\/\/doi.org\/10.1002\/ana.22423","archive":["Portico"],"relation":{},"ISSN":["0364-5134","1531-8249"],"issn-type":[{"value":"0364-5134","type":"print"},{"value":"1531-8249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}